CANY
MRSN

Caxton Associates (New York)’s Mersana Therapeutics MRSN Stock Holding History

Caxton Associates (New York)’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,917
Closed -$221K – 602
2022
Q2 		$221K Buy
+1,917
New +$180K 0.02% 451

Other funds holding MRSN

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Caxton Associates (New York)'s MRSN Position: Q3 2022 in Review

Caxton Associates (New York) sold out of Mersana Therapeutics (MRSN) in Q3 2022, closing a stake of 1,917 shares — an estimated $221K sold.

Caxton Associates (New York) first reported a position in MRSN in Q2 2022 and held it in 1 quarter. The position peaked at $221K in Q2 2022. 152 funds tracked by Wall St. Rank hold MRSN as of Q3 2022.

  • Caxton Associates (New York) reported no remaining Mersana Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Caxton Associates (New York) sold 1,917 Mersana Therapeutics shares in Q3 2022, an estimated $221K.
  • Caxton Associates (New York) first reported a position in Mersana Therapeutics in Q2 2022 and held it in 1 quarter.
  • Caxton Associates (New York)'s Mersana Therapeutics position peaked at $221K in Q2 2022.
  • 152 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q3 2022.

Based on Caxton Associates (New York)'s 13F filing for Q3 2022, filed 14 Nov 2022.